Financials CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:35:24 2025-07-10 pm EDT			5-day change	1st Jan Change
5.455 ^USD	-0.82%		+0.28%	+60.26%

Jul. 01	CureVac N.V. - Shareholder/Analyst Call
Jun. 26	UBS Downgrades CureVac to Neutral From Buy, Adjusts Price Target to $5.50 From $12	MT

Projected Income Statement: CureVac N.V.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	48.9	103	67.42	53.8	535.2	69.05	85.64	144.2
Change	-	110.61%	-34.54%	-20.2%	894.8%	-87.1%	24.03%	68.34%
EBITDA ¹	-99.14	-762.4	-225.7	-250.8	196.5	-99.58	-96.56	-42.25
Change	-	-669.03%	70.4%	-11.12%	178.34%	-150.68%	3.03%	56.25%
EBIT ¹	-109.8	-778.1	-249.5	-274.2	177.7	-97.99	-96.99	-14.18
Change	-	-608.67%	67.94%	-9.92%	164.81%	-155.14%	1.02%	85.38%
Interest Paid	-20.03	-10.34	-3.707	-	-	-	-	-
Earnings before Tax (EBT) ¹	-129.8	-412.5	-249.2	-260	190	-81.48	-101.2	-40.57
Change	-	-217.8%	39.6%	-4.35%	173.08%	-142.88%	-24.22%	59.91%
Net income ¹	-129.1	-411.7	-249	-260.2	162.2	-103.1	-112.1	-49.85
Change	-	-218.86%	39.51%	-4.47%	162.34%	-163.56%	-8.74%	55.53%
Announcement Date	4/15/21	4/28/22	4/25/23	4/24/24	4/10/25	-	-	-

¹EUR in Million

Estimates

Fiscal Period: December	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	34.55	5.162	6	10	22.4	29.36	41.22	24.4	20.1	11.2	11.69	7.129	7.579	16.5	22.6	12.37	14.44	493.9	14.5	0.893	3.338	34.59	32.56
Change	-	-85.06%	16.23%	66.67%	124%	31.09%	40.39%	-40.81%	-17.62%	-44.28%	4.37%	-39.01%	6.31%	117.71%	36.97%	-45.25%	16.67%	3,321.31%	-97.06%	-93.84%	273.78%	936.22%	-5.85%
EBITDA	0.25	-35.93	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-14,472%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-1.58	-36.76	-46.6	-115.8	-170.2	-143.1	-371.4	-15.27	-60.3	-52.4	-121.5	-60.36	-71.8	-54.04	-88	-73.32	-73.62	368.4	-43.8	-54.73	-43.59	21.04	13.02
Change	-	-2,226.46%	-26.78%	-148.5%	-46.98%	15.95%	-159.61%	95.89%	-294.94%	13.1%	-131.89%	50.33%	-18.96%	24.74%	-62.85%	16.69%	-0.41%	600.41%	-111.89%	-24.95%	20.34%	148.26%	-38.09%
Charge d'intérêts	-	0.068	-	-	-	-	-	-	-	-	-7.24	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-12.01	-36.69	-	-112.2	-	-	-4.559	-15.2	-57.6	-	-128.8	-57.42	-67.39	-48.7	-86.5	-69.89	-71.24	370.6	-38.6	-51.66	-41.85	22.59	14.93
Change	-	-205.5%	-	-	-	-	-	-233.41%	-278.95%	-	-	55.4%	-17.36%	27.73%	-77.62%	19.21%	-1.94%	620.19%	-110.42%	-33.82%	18.98%	153.98%	-33.89%
Net income ¹	-10.29	-36.83	-	-113.7	-	-	-1.936	-15.09	-57.58	-	-128.8	-57.42	-67.41	-48.68	-86.65	-70.55	-72.54	338	-32.76	-52.08	-38.93	3.96	4.357
Change	-	-257.96%	-	-	-	-	-	-679.6%	-281.53%	-	-	55.41%	-17.41%	27.79%	-78%	18.58%	-2.82%	565.99%	-109.69%	-58.98%	25.25%	110.17%	10.01%
Announcement Date	1/3/22	11/30/20	4/15/21	5/26/21	8/16/21	12/17/21	4/28/22	5/25/22	8/18/22	11/16/22	4/25/23	5/30/23	8/17/23	11/14/23	4/24/24	5/23/24	8/15/24	11/12/24	4/10/25	5/20/25	-	-	-

¹EUR in Million

Estimates

Forecast Balance Sheet: CureVac N.V.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-1,270	-783	-467	-361	-443	-360	-309	-266
Change	-	38.35%	40.36%	22.7%	-22.71%	18.7%	14.17%	13.92%
Announcement Date	4/15/21	4/28/22	4/25/23	4/24/24	4/10/25	-	-	-

¹EUR in Million

Estimates

Cash Flow Forecast: CureVac N.V.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	36.33	124.2	88.02	52.32	14.32	3.315	2.45	2.318
Change	-	241.94%	-29.14%	-40.56%	-72.64%	-76.84%	-26.09%	-5.41%
Free Cash Flow (FCF) ¹	486.1	-857.4	-374.2	-320.2	87.54	63	-26	52
Change	-	-276.38%	56.35%	14.43%	127.34%	-28.03%	-141.27%	300%
Announcement Date	4/15/21	4/28/22	4/25/23	4/24/24	4/10/25	-	-	-

¹EUR in Million

Estimates

Forecast Financial Ratios: CureVac N.V.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-202.75%	-740.31%	-334.79%	-466.21%	36.71%	-144.21%	-112.75%	-29.31%
EBIT Margin (%)	-224.54%	-755.53%	-370%	-509.67%	33.2%	-141.91%	-113.25%	-9.83%
EBT Margin (%)	-265.44%	-400.52%	-369.56%	-483.27%	35.5%	-118%	-118.18%	-28.14%
Net margin (%)	-264.05%	-399.76%	-369.37%	-483.58%	30.3%	-149.29%	-130.89%	-34.58%
FCF margin (%)	994.02%	-832.46%	-555.03%	-595.18%	16.36%	91.24%	-30.36%	36.07%
FCF / Net Income (%)	-376.45%	208.24%	150.26%	123.08%	53.97%	-61.11%	23.19%	-104.31%
Profitability
ROA	-	-30.84%	-24.67%	-31.56%	20.39%	-5.8%	-10.55%	-
ROE	-38.63%	-58.82%	-40.77%	-49.55%	26.73%	-14.51%	-10.63%	-30.22%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	74.29%	120.62%	130.56%	97.25%	2.67%	4.8%	2.86%	1.61%
CAPEX / EBITDA (%)	-36.64%	-16.29%	-39%	-20.86%	7.29%	-3.33%	-2.54%	-5.49%
CAPEX / FCF (%)	7.47%	-14.49%	-23.52%	-16.34%	16.35%	5.26%	-9.42%	4.46%
Items per share
Cash flow per share ¹	3.952	-3.941	-1.514	-1.213	0.4539	-0.3913	-0.5337	-
Change	-	-199.74%	61.6%	19.86%	137.42%	-186.21%	-36.39%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	5.381	3.679	2.735	2.308	3.105	3.82	3.513	1.875
Change	-	-31.62%	-25.66%	-15.63%	34.52%	23.04%	-8.04%	-46.63%
EPS ¹	-0.98	-2.21	-1.32	-1.18	0.72	-0.4557	-0.4876	-0.2188
Change	-	-125.51%	40.27%	10.61%	161.02%	-163.3%	-6.99%	55.12%
Nbr of stocks (in thousands)	176,460	187,050	190,244	223,924	224,314	225,173	225,173	225,173
Announcement Date	4/15/21	4/28/22	4/25/23	4/24/24	4/10/25	-	-	-